HomeAI · summaries
Storia in 2 fonti
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026…
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology…
- ·
pharmaceutical-technology.com
ASCO26: In vivo oncology approaches continue to show promise
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
- ·
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.